OptiKira logo

OptiKira

Optikira is developing small molecule therapeutics to prevent cell death in pathologies caused by misfolded or unfolded proteins in disease like retinitis pigmentosa, diabetes and amyotrophic lateral sclerosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.optikira.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
20600 Chagrin Boulevard, Suite 210, OH 44122
Cleveland
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Feb 2017, OptiKira Receives $998,500 Grant from ALS Association to accelerate the discovery of new treatments for ALS.

In Sep 2015, OptiKira was awarded with two Small Business Technology Transfer (STTR) grants, from the National Eye Institute (NEI) and from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Additional funding is also provided by BioMotiv associated with The Harrington Project for Discovery & Development, a $250 Mn national initiative for advancing medicine centred at University Hospitals in Cleveland.